ストックスクリーナーアプリを入手
39.74
0.74%
0.29
プレマーケット:
38.51
-1.23
-3.10%
前日終値:
$39.45
開ける：
$40
24時間の取引高:
475.76K
Relative Volume:
0.87
時価総額：
$2.72B
収益：
$35.93M
当期純損益:
$-244.56M
株価収益率:
-10.06
EPS:
-3.95
ネットキャッシュフロー:
$-157.31M
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
-5.04%
6か月 パフォーマンス:
-28.12%
1年 パフォーマンス:
+13.58%
1日の値動き範囲:
$39.22
$40.44
1週間の範囲:
$38.52
$40.44
52週間の値動き範囲:
$33.60
$61.61
Merus N V Stock (MRUS) Company Profile
MRUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
39.74 | 2.72B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-21 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-03-28 | 開始されました | Truist | Buy |
| 2024-03-04 | 繰り返されました | Needham | Buy |
| 2023-11-02 | 開始されました | Canaccord Genuity | Buy |
| 2023-08-21 | 開始されました | TD Cowen | Outperform |
| 2022-08-02 | 開始されました | Stifel | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Needham | Buy |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-06-07 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-08 | 開始されました | William Blair | Outperform |
| 2021-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 再開されました | Guggenheim | Buy |
| 2019-06-28 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 再開されました | Guggenheim | Buy |
| 2019-04-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-03-21 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-12-22 | アップグレード | Citigroup | Neutral → Buy |
| 2016-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-06-13 | 開始されました | Citigroup | Buy |
| 2016-06-13 | 開始されました | Guggenheim | Buy |
| 2016-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Merus N V (MRUS) 最新ニュース
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff (NASDAQ:MRUS) - Seeking Alpha
Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December - MarketBeat
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Will Merus' First Commercialized Drug, Bizengri, Drive Revenue Growth And Propel Stock Price? - RTTNews
(MRUS) Investment Analysis - Stock Traders Daily
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Merus (NASDAQ:MRUS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Merus and Biohaven link up on ADC programs - The Pharma Letter
Merus and Biohaven to co-develop three novel bispecific ADC programs (NASDAQ:MRUS) - Seeking Alpha
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Merus (NASDAQ:MRUS) Stock Price Up 5.1%Here's What Happened - MarketBeat
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday - Benzinga
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’ - MSN
(MRUS) Long Term Investment Analysis - Stock Traders Daily
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Analysts Set Merus (NASDAQ:MRUS) Target Price at $85.64 - MarketBeat
4,122 Shares in Merus (NASDAQ:MRUS) Bought by MML Investors Services LLC - Defense World
Trend Tracker for (MRUS) - Stock Traders Daily
State Street Corp Sells 9,809 Shares of Merus (NASDAQ:MRUS) - Defense World
Swelling losses haven't held back gains for Merus (NASDAQ:MRUS) shareholders since they're up 201% over 5 years - Simply Wall St
HighTower Advisors LLC Purchases Shares of 7,231 Merus (NASDAQ:MRUS) - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - The Manila Times
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) versus Can-Fite BioPharma (NYSE:CANF) Critical Survey - Defense World
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy - Insider Monkey
Merus (NASDAQ:MRUS) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Wellington Management Group LLP Grows Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus’ (MRUS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Citi raises Merus target to $97 on positive trial data By Investing.com - Investing.com South Africa
Citi raises Merus target to $97 on positive trial data - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Merus (NASDAQ:MRUS) - MarketBeat
The Manufacturers Life Insurance Company Has $2.56 Million Stock Position in Merus (NASDAQ:MRUS) - Defense World
Positive early data on Merus’ petosemtamab - The Pharma Letter
The Manufacturers Life Insurance Company Sells 11,463 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus N V (MRUS) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):